cas 1454847-99-4|| where to buy methyl 2-[(1R)-1-(2-aminopyridin-3-yl)oxyethyl]-4-fluorobenzoate

Nombre del producto:methyl 2-[(1R)-1-(2-aminopyridin-3-yl)oxyethyl]-4-fluorobenzoate

IUPAC Name:methyl 2-[(1R)-1-[(2-aminopyridin-3-yl)oxy]ethyl]-4-fluorobenzoate

Unidad de embalaje	Stock disponible	Precio($)
CM336707-100mg	in stock	ǯźƻ
CM336707-250mg	in stock	Ŕźź

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1454847-99-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1454847-99-4; Fórmula molecular:C15H15FN2O3; Punto de fusión:-; Código de sonrisas:O=C(OC)C1=CC=C(F)C=C1[C@H](OC2=CC=CN=C2N)C; Densidad:

: Número de catálogo:CM336707; Peso molecular:290.29; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Pyridines; Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.; Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu; Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer; Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

: Lorlatinib; Pfizer announced longer-term follow-up results of the Phase 3 CROWN study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This study aims to evaluate the efficacy and safety of the third-generation anaplastic lymphoma kinase (ALK) inhibitor LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The analysis showed that compared with the first-generation ALK inhibitors, the risk of disease progression or death in patients treated with lorlatinib continued to decrease by 81%, and the risk of brain metastasis progression was reduced by 94%.